Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 9/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11973763 | 0.86 | SLC40A1 (0.74) | SLC40A1KDM4EGAABRD4CREBBP | |
| SCHEMBL11973035 | 0.83 | SLC40A1 (1.00) | SLC40A1CREBBPALDH1A1MEN1KMT2A | |
| SCHEMBL30553397 | 0.83 | SLC40A1 (0.69) | SLC40A1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL11972802 | 0.83 | SLC40A1 (0.69) | SLC40A1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL30925584 | 0.79 | SLC40A1 (0.72) | SLC40A1GAAMEN1KMT2ATDP1 | |
| SCHEMBL17506516 | 0.79 | SLC40A1 (0.82) | SLC40A1KDM4EGAAALDH1A1MEN1 | |
| SCHEMBL27214322 | 0.79 | SLC40A1 (0.72) | SLC40A1KDM4EGAACREBBPALDH1A1 | |
| SCHEMBL30925456 | 0.79 | SLC40A1 (0.72) | SLC40A1KDM4EGAACREBBPALDH1A1 | |
| SCHEMBL11997098 | 0.78 | SLC40A1 (0.55) | SLC40A1KDM4EGAAALDH1A1MEN1 | |
| SCHEMBL30553404 | 0.77 | SLC40A1 (0.76) | SLC40A1CREBBPALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885KDM4E 4215/4885GAA 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.